Table 2.
The association between the CpG site methylation of KCNQ1OT1 and the risk of breast cancer in the validation dataset.
| CpG_Position | Δβ | p (t-Test) | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) a | p | |||
| KCNQ1OT1_2721952 | −0.011 | 0.022 | 0.834 (0.714–0.973) | 0.021 | 0.835 (0.711–0.978) | 0.026 |
| KCNQ1OT1_2721955 | −0.012 | 0.017 | 0.829 (0.709–0.966) | 0.017 | 0.828 (0.705–0.970) | 0.020 |
| KCNQ1OT1_2721961 | −0.012 | 0.019 | 0.831 (0.712–0.969) | 0.019 | 0.828 (0.705–0.971) | 0.021 |
| KCNQ1OT1_2721966 | −0.012 | 0.021 | 0.834 (0.714–0.972) | 0.021 | 0.834 (0.710–0.977) | 0.025 |
| KCNQ1OT1_2721968 | −0.011 | 0.025 | 0.838 (0.717–0.977) | 0.025 | 0.836 (0.712–0.979) | 0.027 |
| KCNQ1OT1_2721978 | −0.012 | 0.015 | 0.825 (0.706–0.962) | 0.015 | 0.823 (0.701–0.965) | 0.017 |
| KCNQ1OT1_2721982 | −0.012 | 0.015 | 0.825 (0.706–0.962) | 0.015 | 0.822 (0.700–0.963) | 0.016 |
| KCNQ1OT1_2721986 | −0.012 | 0.019 | 0.831 (0.711–0.969) | 0.019 | 0.828 (0.705–0.971) | 0.021 |
| KCNQ1OT1_2721992 | −0.012 | 0.014 | 0.824 (0.705–0.961) | 0.014 | 0.820 (0.698–0.961) | 0.015 |
| KCNQ1OT1_2722019 | −0.011 | 0.023 | 0.836 (0.716–0.975) | 0.023 | 0.836 (0.712–0.979) | 0.027 |
| KCNQ1OT1_2722023 | −0.012 | 0.013 | 0.822 (0.704–0.959) | 0.013 | 0.820 (0.698–0.961) | 0.015 |
| KCNQ1OT1_2722036 | −0.012 | 0.017 | 0.829 (0.710–0.967) | 0.017 | 0.829 (0.706–0.971) | 0.021 |
| KCNQ1OT1_2722038 | −0.012 | 0.015 | 0.825 (0.706–0.962) | 0.015 | 0.823 (0.701–0.964) | 0.017 |
| KCNQ1OT1_2722045 | −0.012 | 0.018 | 0.829 (0.710–0.967) | 0.018 | 0.828 (0.705–0.970) | 0.020 |
| KCNQ1OT1_2722062 | −0.011 | 0.024 | 0.837 (0.717–0.976) | 0.024 | 0.835 (0.711–0.979) | 0.027 |
| KCNQ1OT1_2722071 | −0.011 | 0.020 | 0.833 (0.713–0.971) | 0.020 | 0.832 (0.708–0.975) | 0.023 |
| KCNQ1OT1_2722073 | −0.012 | 0.015 | 0.826 (0.707–0.963) | 0.015 | 0.823 (0.701–0.965) | 0.017 |
| KCNQ1OT1_2722076 | −0.012 | 0.016 | 0.828 (0.708–0.965) | 0.016 | 0.824 (0.701–0.965) | 0.017 |
| KCNQ1OT1_2722082 | −0.012 | 0.019 | 0.831 (0.711–0.969) | 0.019 | 0.829 (0.705–0.971) | 0.021 |
| KCNQ1OT1_2722084 | −0.011 | 0.024 | 0.837 (0.717–0.976) | 0.024 | 0.834 (0.710–0.977) | 0.025 |
| KCNQ1OT1_2722086 | −0.011 | 0.025 | 0.838 (0.718–0.977) | 0.025 | 0.833 (0.709–0.976) | 0.025 |
| KCNQ1OT1_2722119 | −0.031 | 0.009 | 0.814 (0.693–0.951) | 0.010 | 0.834 (0.707–0.979) | 0.028 |
Δβ represents the differential methylation of CpG sites between breast cancer patients and controls from the validation dataset, and the ORs were calculated based on the methylation levels increasing per standard deviation. a ORs of multivariate analyses were adjusted for age, BMI, race, location, family history of other cancers, and family history of breast cancer.